Pancragen for Health & Longevity

Evidence Review created on 09/01/2026 using AI4L / Opus 5

Also known as: KEDW, Lys-Glu-Asp-Trp, Lys-Glu-Asp-Trp-NH2

Motivation

Pancragen is a synthetic peptide built from four amino acid building blocks and directed at the pancreas, the organ that releases insulin and digestive enzymes. It was designed in Russia as a signaling molecule rather than a hormone: the claim attached to it is that it enters the cell nucleus and adjusts which genes the pancreas reads, rather than acting on a surface receptor the way a drug normally does.

It belongs to a family of short peptides first extracted from animal organs by Soviet researchers in the 1970s and later reproduced synthetically. Within Russia and neighbouring countries these preparations are registered as supplements and used in clinical practice; elsewhere they reach people almost entirely through online sellers. Attention has followed the observation that blood sugar regulation tends to drift as people get older, and the pancreas is where that drift begins.

This review examines what is established about Pancragen and what is not: its composition, the proposed mechanism, what laboratory, animal and human studies actually report, where the evidence is thin or comes from a single source, and what risks and practical limits accompany its use.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Pancragen

Covers the tetrapeptide’s chemistry, its development by Khavinson’s group, the proposed gene-regulation mechanism, and the cell-culture, rat, rhesus monkey and elderly human findings, alongside safety and regulatory status.

Examine

No Examine article exists for Pancragen. Examine.com indexes dietary supplements and nutrients with human trial evidence, and does not cover synthetic peptides distributed outside regulated supplement channels.

ConsumerLab

No ConsumerLab article exists for Pancragen. ConsumerLab tests retail supplement products sold through mainstream channels, and Pancragen is not marketed as such a product in the markets it covers.

Systematic Reviews

The single systematic review touching this compound addresses its proposed molecular mechanism rather than any clinical outcome.

Peptide Regulation of Gene Expression: A Systematic Review - Khavinson et al., 2021

Systematic review of peptide–DNA interactions that names KEDW, the tetrapeptide sold as Pancragen, among short peptides shown to bind histone proteins and gene promoter regions.

Pancragen carries a clear trade-off between a claimed metabolic benefit and an undocumented safety profile, and only the benefit side has any systematic review coverage at all. No systematic review or meta-analysis examines Pancragen’s clinical effects, its adverse events, or the opportunity cost of using it in place of an established glucose-lowering agent; the risk side of the trade-off is entirely unrepresented in this literature.

Mechanism of Action

Pancragen is the tetrapeptide Lys-Glu-Asp-Trp, roughly 576 daltons (a unit of molecular mass). The proposed mechanism is not receptor-mediated. Because the molecule is small, it is held to cross the cell and nuclear membranes and bind directly to DNA and to histones (the spool proteins that DNA is wound around), opening promoter regions so genes can be transcribed. Molecular docking places its preferred DNA contact at a short “acct” sequence, as reported by Khavinson et al., 2016.

In aged human pancreatic cell cultures the peptide raises expression of PDX1, PTF1A, PAX4, PAX6, FOXA2 and NKX2-2, transcription factors (proteins that switch genes on) specifying insulin-producing islet and enzyme-producing acinar cell identity (Khavinson et al., 2013). It also alters DNA methylation (a chemical tag that silences genes) at several of those promoters (Ashapkin et al., 2015).

Pharmacologically it behaves as a peptide, not a small molecule: hydrolysis by peptidases to free amino acids, no involvement of cytochrome P450 (the liver’s principal drug-metabolising enzyme family), and proposed uptake through the PEPT and LAT carriers (membrane transporters for di-peptides and amino acids), which is the argument offered for tissue selectivity (Khavinson et al., 2022). No human pharmacokinetic study exists, so half-life and tissue distribution in people are unmeasured; comparable ultrashort peptides clear plasma within minutes.

The competing mechanistic reading is that a four-residue peptide is hydrolysed to its constituent amino acids before reaching any target, so oral effects would reflect amino acid supply or non-specific signaling rather than sequence-directed gene regulation.

Historical Context & Evolution

The lineage begins in Soviet military medicine in the 1970s, when Morozov and Khavinson at the Kirov Military Medical Academy isolated low-molecular-weight peptide fractions from calf thymus and pineal tissue. These preparations, termed cytomedines, were meant to restore immune and endocrine function in personnel exposed to radiation and extreme stress; Thymalin and Epithalamin came from that work. A pancreatic extract followed the same template.

Through the 1990s and 2000s the St. Petersburg Institute of Bioregulation and Gerontology moved from organ extracts to synthetic fragments, reasoning that an extract’s activity resides in a short peptide sequence. Lys-Glu-Asp-Trp was designated the pancreatic member and named Pancragen.

It came to be considered for health optimization for two reasons. The group reported that related peptides in the family extended mean lifespan and reduced tumor incidence in rodents and shifted age-related biomarkers (Anisimov & Khavinson, 2010). Separately, the proposed mechanism moved from vague “bioregulation” to a testable epigenetic claim once DNA-binding and gene-expression data appeared, which made the peptides legible to a longevity audience.

What changed on the skeptical side is the scope of independent confirmation, not a refutation. The core findings have not been overturned; they have largely not been reproduced outside the originating institute, and most reports appear in a narrow set of journals. What changed on the supporting side is that mainstream reviews now accept that short peptides can enter cells and reach intracellular targets (Apostolopoulos et al., 2021), removing one earlier objection without validating the clinical claims.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the only human outcome evidence is a single small controlled study of glycemic markers in older adults, with no replication in a second human trial, and every other supporting result comes from in-vitro cell culture or animal experiments.

Medium 🟩 🟩

Improved Glucose Tolerance and Reduced Insulin Resistance in Older Adults with Type 2 Diabetes

In a controlled study of older adults, Pancragen lowered fasting glucose, lowered glucose during a standard oral glucose tolerance test, and reduced circulating insulin and an insulin resistance index, while untreated participants showed no change (Korkushko et al., 2011). The proposed mechanism is restored islet function; old rhesus monkeys showed matching corrections in glucose clearance and insulin output (Goncharova et al., 2014). This is one small trial from the originating institute’s collaborating group, with no independent replication, no long-term follow-up, and no report of how adverse events were captured.

Magnitude: The direction is downward for fasting glucose, post-load glucose, circulating insulin and the insulin resistance index, and it holds in older adults who already have type 2 diabetes, the only group given the peptide; the published report states significance without giving effect sizes, so the literature provides no outcome figure.

Low 🟩

Speculative 🟨

Pancreatic Cell Differentiation, Digestive Enzyme Capacity and Reduced Cell Death

In aged human pancreatic cultures the peptide raised islet and digestive-enzyme-cell differentiation factors (Khavinson et al., 2013) and cell-death-resisting markers (Khavinson et al., 2012), the basis for its chronic pancreatitis claim. No clinical outcome link.

Endothelial and Microvascular Protection in Early Diabetes

In rats with chemically induced diabetes, oral Pancragen lowered blood glucose and intramuscular dosing normalized capillary endothelial adhesion without changing permeability (Khavinson et al., 2007). Rodent model only; no human vascular endpoint has been measured.

Benefit-Modifying Factors

Baseline glycemic status: Benefit appeared only where glucose regulation was already impaired. Metabolically healthy older adults in the same study were not given the peptide, so there is no evidence of headroom in people whose fasting glucose and insulin are already in range.
Baseline melatonin and pineal function: Korkushko et al., 2011 linked reduced night-time melatonin output to insulin resistance in the same population, raising the possibility that people with disrupted circadian melatonin production are the group in whom any effect concentrated.
Genetic polymorphisms: No pharmacogenetic data exist. Plausible modifiers are variants in SLC15A1 and SLC7A5 (genes encoding the peptide and amino acid transporters proposed to carry the molecule into cells) and TCF7L2 (a gene variant reducing insulin secretion capacity).
Pre-existing health conditions: Any benefit presupposes surviving insulin-producing tissue. Autoimmune type 1 diabetes, prior pancreatic resection, and chronic pancreatitis with established fibrosis leave little functional tissue for a differentiation-based mechanism to act on.
Age-related considerations: All human and primate work used aged subjects, and the effects were framed as correcting an age-related decline. At the older end of the target range the population match is closest; in younger adults there is no supporting data.
Sex-based differences: None have been reported. The primate work used female animals exclusively, and the human report does not break results down by sex, so any sex difference in response is simply unstudied.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no adverse outcome has been documented in more than one human trial, because the single published human study reports no systematic recording of adverse events, and no pharmacovigilance system (the databases that collect drug side-effect reports) covers this compound.

Medium 🟥 🟥

No risk reaches Medium either: there is no individual human trial and no consistent observational dataset reporting adverse outcomes with this tetrapeptide, so the only human-relevant safety signals available are indirect ones drawn from the drug class it is combined with and from the channel it is sold through.

Low 🟥

Additive Blood Glucose Lowering and Hypoglycemia

Both human and primate studies report glucose lowering; the primate work benchmarked the peptide against glimepiride, a sulfonylurea (a class making the pancreas release insulin) (Goncharova et al., 2015). Combined with insulin or a sulfonylurea, this risks hypoglycemia (dangerously low blood glucose). No study has co-administered them.

Magnitude: The direction is downward for fasting and post-load glucose whenever a glucose-lowering effect occurs, and the risk holds specifically where an insulin-releasing drug or injected insulin is already in use; no study has quantified hypoglycemia incidence with this peptide, so the literature provides no outcome figure.

Substandard, Contaminated or Misidentified Product from Unregulated Sellers

Pancragen reaches most non-Russian buyers through unregulated online vendors. Surveillance of peptide products bought without prescription from illegal online pharmacies found large deviations from labeled content and purity, plus endotoxin (bacterial cell-wall debris that provokes fever and inflammation), as reported by Ashraf et al., 2024.

Magnitude: In that surveillance study measured purity was 7.7% to 14.4% against a 99% label claim, active content exceeded the label by 28.6% to 38.7%, and endotoxin was present in every sample at 2.16 to 8.95 endotoxin units per milligram; no equivalent testing has been published for bioregulator peptides specifically.

Speculative 🟨

Proliferative and Cell-Death-Resisting Signaling in Pancreatic Tissue

In aged human pancreatic cultures the peptide raised proliferation markers and lowered p53 (a tumor-suppressing protein) (Khavinson et al., 2012). The oncological implication is mechanistic only; no animal or human tumor data exist.

Hypersensitivity and Injection-Site Reactions

Injectable presentations carry the generic risks of local reaction and hypersensitivity, and no immunogenicity testing has been published for this tetrapeptide. The basis is class-level reasoning and isolated reports, not controlled observation.

Risk-Modifying Factors

Concurrent glucose-lowering therapy: The dominant modifier. Insulin and insulin-releasing drugs convert an additive glucose-lowering effect into a hypoglycemic event; participants on metformin or lifestyle measures alone carry far less exposure to that pathway.
Baseline biomarker levels: A low starting HbA1c (glycated hemoglobin, a three-month average of blood sugar) leaves less margin before hypoglycemia, and documented hypoglycemia unawareness removes the warning symptoms that would otherwise prompt correction.
Genetic polymorphisms: Reduced-function CYP2C9 variants (CYP2C9 is an enzyme that clears several sulfonylureas) prolong those drugs’ action and amplify any additive glucose lowering. No polymorphism has been shown to modify the peptide’s own handling.
Pre-existing health conditions: Impaired kidney or liver function prolongs co-administered glucose-lowering drugs. A personal history of pancreatic cancer is the condition where the proliferative signaling seen in cell culture is least acceptable as an unknown.
Age-related considerations: Older adults, particularly at the upper end of the target range, tolerate hypoglycemia poorly, are more often taking several glucose-lowering agents, and are the exact population the human data were generated in.
Sex-based differences: No sex difference in adverse effects has been reported, and none can be ruled out: the primate safety observations came from female animals only and the human report gives no sex-stratified safety data.

Key Interactions & Contraindications

Insulin and insulin secretagogues (drugs prompting insulin release): Insulin, sulfonylureas (glimepiride, glipizide, glibenclamide) and meglitinides (repaglinide, nateglinide, a second insulin-releasing class). Severity: caution with active monitoring. Consequence: additive hypoglycemia. Mitigation: those doses are reviewed before starting, with fasting and post-meal glucose monitored.
Other prescription glucose-lowering agents: Glucagon-like peptide-1 receptor agonists (semaglutide, liraglutide; mimicking a gut hormone that stimulates insulin release) and sodium-glucose cotransporter-2 inhibitors (empagliflozin, dapagliflozin; making the kidney excrete glucose). Severity: monitor. Consequence: additive glucose lowering. Mitigation: fasting glucose is checked weekly during a course.
Over-the-counter medications: High-dose niacin (vitamin B3) raises fasting glucose and can mask any effect; high-dose salicylates (a pain-relieving class: aspirin, salsalate) lower it and add to the effect. Severity: monitor. Consequence: obscured or amplified glycemic change. Mitigation: dose changes are held during a course.
Supplements with additive glucose-lowering effects: Berberine, chromium picolinate, alpha-lipoic acid, Gymnema sylvestre and cinnamon extract all lower glucose. Severity: caution. Consequence: additive hypoglycemia when combined. Mitigation: agents are introduced one at a time rather than as a combined protocol.
Other interventions: Prolonged fasting, ketogenic or very-low-carbohydrate eating and prolonged endurance exercise all lower glucose independently. Severity: caution. Consequence: additive hypoglycemia. Mitigation: courses are not started during a fasting or dietary transition period.

Populations who should avoid Pancragen:

Pregnancy and lactation, at any stage, given the complete absence of reproductive toxicity data
Autoimmune type 1 diabetes, and latent autoimmune diabetes in adults, where insulin-producing cell mass is destroyed rather than aged
Documented hypoglycemia unawareness, or HbA1c below 6.5% while on insulin or a sulfonylurea
Acute pancreatitis, active or within the preceding 90 days
Personal history of pancreatic cancer, or of pre-cancerous pancreatic changes found on imaging or biopsy
Known hypersensitivity to the peptide or to excipients (inactive ingredients) in a specific preparation

Risk Mitigation Strategies

Baseline and on-course glucose measurement: Fasting glucose, HbA1c and fasting insulin before the first course, with fasting glucose repeated at day 5 and day 10. This detects the additive hypoglycemia that co-administration with insulin or a sulfonylurea produces.
Pre-emptive review of glucose-lowering medication: Where insulin or a sulfonylurea is in use, the dose is reviewed with the prescribing clinician before a course rather than after a low reading, which prevents symptomatic hypoglycemia instead of reacting to it.
Certificate of analysis before purchase: Batch-specific identity by mass spectrometry, purity by chromatography above 98%, and endotoxin below 0.5 endotoxin units per milligram. This addresses the substandard content, mislabeled purity and endotoxin contamination documented in unregulated peptide supply.
Single short course before repeating: One 10 to 20 day course completed and assessed before any repeat. This limits total exposure to a compound whose proliferative signaling in pancreatic cell culture has no long-term human safety data.
Defined stop rules: Discontinuation on any hypoglycemic episode, new abdominal pain radiating to the back, rash or firm swelling at an injection site. These correspond respectively to additive glucose lowering, pancreatic inflammation and hypersensitivity.

Therapeutic Protocol

Standard course as used by practitioners: The St. Petersburg Institute of Bioregulation and Gerontology, which licenses the commercial product, and clinics following its protocols use oral capsules daily for 10 to 20 days, repeated two to three times yearly.
Published research dosing differs from commercial dosing: Goncharova et al., 2015 used 50 micrograms intramuscularly per animal daily for 10 days in primates. Commercial capsules are labeled at 10 to 20 milligrams total content, the tetrapeptide an undisclosed fraction.
Competing approaches: An oral capsule course, an injectable course of the synthetic tetrapeptide, and conventional metformin plus lifestyle modification are three distinct strategies for one endpoint. None has been compared head-to-head against another.
Best time of day: Capsule protocols specify morning administration on an empty stomach, 20 to 30 minutes before food, on the reasoning that peptide transporters in the gut compete with dietary protein fragments. No timing comparison has been tested.
Half-life: Unmeasured in humans. Short peptides of this size are hydrolysed by plasma and gut peptidases within minutes, which is why courses are structured around cumulative gene-expression effects rather than sustained circulating concentrations.
Single versus split dosing: Protocols use a single daily dose. With a half-life of minutes, splitting would not extend exposure meaningfully, and the proposed mechanism is a transcriptional change rather than a concentration-dependent receptor effect.
Genetic polymorphisms influencing dose: None validated. Variants in SLC15A1 and SLC7A5, encoding the transporters proposed to carry the peptide into cells, are the theoretically relevant candidates, but no pharmacogenetic study of this compound has been performed.
Sex-based differences: No dosing difference has been established. Primate data came from females only and the human report does not stratify by sex, so identical protocols are used for men and women by default rather than by evidence.
Age-related considerations: All supporting data come from aged subjects. At the upper end of the target range, the case for lower starting exposure rests on hypoglycemia tolerance and concurrent medications, not on any age-specific pharmacokinetic finding.
Baseline biomarkers influencing response: Fasting glucose, fasting insulin and an insulin resistance index define the population in which an effect was seen. Values already optimal predict no measurable response, since the reported effect was correction of an impairment.
Pre-existing conditions influencing response: Residual insulin-producing cell mass is the limiting factor. Long-standing insulin-requiring diabetes, prior pancreatic resection and advanced chronic pancreatitis leave little tissue for a differentiation-based mechanism to act upon.

Discontinuation & Cycling

Not intended as lifelong therapy: Every published and commercial protocol is course-based. The peptide is administered for a defined period and stopped, in contrast to metformin or insulin, which are used continuously for as long as the metabolic indication persists.
No withdrawal effects reported: No rebound high blood glucose, dependence or discontinuation syndrome appears in any published study. Goncharova et al., 2014 reported the metabolic effect decaying gradually rather than reversing abruptly after the peptide stopped.
No tapering protocol: Courses end abruptly at day 10 to 20 with no dose reduction step. Since no withdrawal phenomenon has been reported and the half-life is minutes, no pharmacological rationale for tapering has been proposed.
Cycling is the standard pattern: Two to three courses yearly, separated by several months, justified on the reasoning that transcriptional effects persist after dosing stops. The interval is asserted by the product-licensing institute, not established by any comparison study.
Effect persistence after stopping: In old monkeys (Goncharova et al., 2014), the improvement in pancreatic endocrine response was partially retained three weeks after the last dose, which is the only objective observation supporting a course-based rather than continuous schedule.

Sourcing and Quality

Two distinct product categories: Russian-registered oral capsule preparations sold as supplements, and lyophilized (freeze-dried) synthetic tetrapeptide vials sold by research chemical vendors. These differ in composition, labeling standards and legal status, and are not interchangeable.
What to verify: A batch-specific certificate of analysis showing identity by mass spectrometry, purity above 98% by high-performance liquid chromatography, and endotoxin testing. Vendor purity claims without a batch-matched third-party report proved unreliable in market surveillance (Ashraf et al., 2024).
Third-party testing is the decisive filter: Independent laboratory verification of a purchased batch, not of a reference batch supplied by the seller, is the only check that catches the content and purity deviations documented in unregulated peptide supply chains.
Reputable sources: No compounding pharmacy or supplement brand covered by independent testing organizations carries this peptide. In practice the Russian manufacturers that hold the original registration are the only sources with a documented regulatory filing behind the product.
Formulation considerations: Capsules combine the peptide with excipients at an undisclosed ratio, so the delivered peptide quantity cannot be reconciled with research doses. Injectable powder requires reconstitution with sterile diluent and refrigerated storage at 2 to 8 degrees Celsius.

Practical Considerations

Time to effect: Korkushko et al., 2011 measured metabolic endpoints over days to weeks, and the primate work (Goncharova et al., 2014) showed changes within a 10-day course. Marketing claims of effects emerging over months rest on no measured timeline.
Common pitfall — treating capsule milligrams as peptide dose: The 10 to 20 milligram capsule figure describes total content including excipients, not tetrapeptide quantity, so it cannot be compared with the microgram research doses or used for dose escalation reasoning.
Common pitfall — combining several bioregulators simultaneously: Vendor protocols combine several organ-directed peptides in one course. This makes any response uninterpretable and multiplies exposure to unregulated product, without any study having tested a combination.
Regulatory status: Registered in Russia as a supplement rather than as a medicine. It holds no marketing authorization from the United States Food and Drug Administration or the European Medicines Agency, and is sold elsewhere as a research chemical not for human use.
Cost and accessibility: Entirely self-funded outside its registration market, with no insurer or national health system reimbursement, and reachable in most countries only through vendors shipping a product labeled as not for human use.
Payer incentives shape which comparison gets studied: The established comparator, metformin, is an inexpensive generic that insurers and national health systems actively favor. No institutional payer gains from funding a trial against a self-funded alternative, which is a structural reason this comparison stays unstudied.

Interaction with Foundational Habits

Sleep: Indirect and bidirectional. Korkushko et al., 2011 tied reduced night-time melatonin output to insulin resistance in the same older population, so poor circadian sleep timing plausibly works against the metabolic endpoint. No study has measured sleep quality as an outcome of the peptide itself, and no sedating or stimulating effect has been reported.
Nutrition: Direct and additive on the glycemic endpoint. Carbohydrate restriction lowers fasting and post-meal glucose through an independent route, which compounds any effect and increases hypoglycemia exposure when a secretagogue is also in use. Capsule protocols specify an empty stomach, since dietary protein fragments compete for the same intestinal peptide transporters.
Exercise: Additive and unstudied in combination. Aerobic and resistance training both improve insulin sensitivity through muscle glucose uptake, a mechanism entirely separate from pancreatic gene expression. No blunting effect on training adaptation has been described, and no timing relationship to dosing has been tested in any species.
Stress management: Indirect. Sustained elevation of cortisol (the main stress hormone) raises liver glucose output and worsens insulin resistance, opposing the claimed benefit; the peptide family’s original Soviet indication was stress and radiation exposure, but no cortisol or stress-axis endpoint has been measured for this specific tetrapeptide in humans.

Monitoring Protocol & Defining Success

Baseline testing establishes whether the metabolic impairment the peptide was studied in is actually present, and whether there is enough glycemic margin for additive glucose lowering to be safe. A pre-course panel covers fasting glucose, HbA1c, fasting insulin, an insulin resistance index calculated from the two, C-peptide (a marker of the pancreas’s own insulin output), a lipid panel, and liver and kidney chemistry. Pancreatic enzymes are added where there is any prior pancreatic history.

Ongoing monitoring follows the course structure rather than a continuous schedule: fasting glucose at day 5 and day 10 of a course, the full glycemic panel at course completion and again 8 to 12 weeks afterwards, and a repeat before each subsequent course. Where courses are repeated two to three times yearly, this produces a comparison against the individual’s own pre-course values rather than against a population reference.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Fasting glucose	75–85 mg/dL	Primary endpoint and the earliest hypoglycemia signal	8–12 hour fast; conventional range extends to 99 mg/dL, which accepts values most functional practitioners already treat
HbA1c	4.9–5.3%	Three-month glycemic average; confirms a real shift rather than a single low reading	HbA1c means glycated hemoglobin; falsely low in anemia or shortened red cell survival; conventional cut-off is 5.7%
Fasting insulin	2–5 µIU/mL	Detects the raised insulin output the peptide was reported to reduce	Same draw as fasting glucose; most conventional laboratories report up to 25 µIU/mL as normal
HOMA-IR	Below 1.0	Calculated insulin resistance index; the endpoint the human study reported	HOMA-IR means homeostatic model assessment of insulin resistance, derived from paired fasting glucose and insulin; conventional thresholds for insulin resistance sit far higher, around 2.5
C-peptide (fasting)	0.8–2.0 ng/mL	Indicates how much insulin the pancreas itself produces, distinguishing residual function from exogenous insulin	Fasting draw; low values point to autoimmune diabetes, a listed contraindication; conventional laboratory ranges run to roughly 3.9 ng/mL
Amylase and lipase	No functional target is established; track stability against the individual’s own pre-course values	Screens for pancreatic inflammation before and during a course	Pancreatic enzymes released into blood; indicated where there is prior pancreatic history or new abdominal pain
eGFR and liver enzymes	eGFR above 90 mL/min/1.73 m²; ALT below 25 U/L	Establishes clearance capacity for co-administered glucose-lowering drugs	eGFR means estimated glomerular filtration rate, a calculated measure of kidney function; ALT is a liver enzyme; conventional cut-offs are far looser, at eGFR 60 mL/min/1.73 m² and ALT 40 U/L
hsCRP	Below 0.5 mg/L	Tracks the low-grade inflammation that accompanies insulin resistance	hsCRP means high-sensitivity C-reactive protein; conventional cut-off is 1.0 mg/L for low risk, with up to 3.0 mg/L reported as average risk; invalid within two weeks of infection or injury

Qualitative markers worth tracking alongside the laboratory panel:

Post-meal energy stability, particularly the absence of an afternoon slump following a carbohydrate-containing lunch
Hypoglycemic symptoms — tremor, sweating, disproportionate hunger — which signal additive glucose lowering rather than benefit
Sleep continuity and consistency of sleep timing, given the melatonin association reported in the same population
Abdominal comfort after meals, since new upper abdominal pain radiating to the back is a stop signal
Injection-site appearance where an injectable preparation is used, tracking firm swelling or persistent redness

Emerging Research

No registered trial exists: A ClinicalTrials.gov search returned no interventional or observational study of Pancragen or the tetrapeptide Lys-Glu-Asp-Trp. For a longevity-oriented reader assessing this compound, that absence across four decades is itself the central finding of this section.
The trial design this compound lacks: NCT07505745, a Phase 2a randomized double-blind placebo-controlled study of the mitochondrial-derived peptide MOTS-c in 120 adults with prediabetes, uses an oral glucose tolerance test insulin sensitivity index as its primary endpoint. It is the template a Pancragen trial would follow.
Evidence that could strengthen the case: Independent replication of the pancreatic transcription-factor findings of Khavinson et al., 2013 in aged human islet cultures, performed outside the originating institute, would move the mechanism from single-group observation toward an established one.
Evidence that could weaken the case: A human pharmacokinetic study would test whether an oral tetrapeptide survives digestion intact. The transporter argument of Khavinson et al., 2022 rests on molecular modeling and cell data, not on measured absorption in people.
Surveillance gap that current work could close: No pharmacovigilance system captures adverse events for peptides sold outside regulated channels. The market surveillance and laboratory testing approach applied to semaglutide by Ashraf et al., 2024 is directly transferable to bioregulator vendors.

Conclusion

Pancragen is a four-amino-acid peptide directed at the pancreas, proposed to work by entering the cell nucleus and adjusting which genes pancreatic tissue reads rather than by acting on a receptor. The case for it rests on one small controlled study in older adults with type 2 diabetes, where measures of blood sugar and insulin fell while untreated participants showed no change, supported by work in old monkeys, in diabetic rats and in aging human pancreatic cell cultures.

That case has a specific shape. The direction of effect is consistent across every level of evidence, but almost the entire body of work comes from one institute in St. Petersburg and its collaborators — the same organization that developed the peptide and licenses the product — and has not been reproduced independently. Nothing has been overturned; very little has been confirmed by outsiders.

The safety picture is thinner still. No adverse event has been systematically recorded in any human study, no registry collects reports, and the two identifiable concerns are practical rather than exotic: added blood sugar lowering on top of existing diabetes medication, and product bought through unregulated sellers whose content and purity have repeatedly failed testing for other peptides.

For someone with measurable metabolic impairment and a tolerance for uncertainty, this is an early-stage compound with a coherent mechanism, one supportive human result, and no independent verification of either.

Top - Benefits - Risks - Protocol

Pancragen for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Medium 🟩 🟩

Improved Glucose Tolerance and Reduced Insulin Resistance in Older Adults with Type 2 Diabetes

Low 🟩

Speculative 🟨

Pancreatic Cell Differentiation, Digestive Enzyme Capacity and Reduced Cell Death

Endothelial and Microvascular Protection in Early Diabetes

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Medium 🟥 🟥

Low 🟥

Additive Blood Glucose Lowering and Hypoglycemia

Substandard, Contaminated or Misidentified Product from Unregulated Sellers

Speculative 🟨

Proliferative and Cell-Death-Resisting Signaling in Pancreatic Tissue

Hypersensitivity and Injection-Site Reactions

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion